Efficacy and safety of temsirolimus in Japanese patients with metastatic renal cell carcinoma on hemodialysis

International Journal of Clinical Oncology

Volumn 18, Issue 6, 2013, Pages 1054-1059

  Miyake, Hideaki ^a   Harada, Ken Ichi ^a   Kusuda, Yuji ^a   Fujisawa, Masato ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Hemodialysis; Renal cell carcinoma; Temsirolimus

Indexed keywords

TEMSIROLIMUS;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER CONTROL; CLINICAL ARTICLE; CLINICAL EVALUATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEMODIALYSIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; JAPANESE; KARNOFSKY PERFORMANCE STATUS; KIDNEY METASTASIS; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; MOUTH ULCER; NEPHRECTOMY; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; RASH; RISK ASSESSMENT; THROMBOCYTHEMIA; THROMBOCYTOPENIA; TREATMENT DURATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; RENAL DIALYSIS; RETROSPECTIVE STUDIES; SIROLIMUS;

EID: 84891484713     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-012-0492-7     Document Type: Article

References (25)

1. Parton M, Gore M, Eisen T (2006) Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer. J Clin Oncol 24:5584-5592
2. Bellmunt J, Montagut C, Albiol S et al (2007) Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents. BJU Int 99:274-280
3. Reeves DJ, Liu CY (2009) Treatment of metastatic renal cell carcinoma. Cancer Chemother Pharmacol 64:11-25
4. Shor B, Zhang WG, Toral-Barza L et al (2008) A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis. Cancer Res 68:2934-2943
5. Del Bufalo D, Ciuffreda L, Trisciuoglio D et al (2006) Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 66:5549-5554
6. Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alpha, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271-2281
7. Miller DC, Schonlau M, Litwin MS et al (2008) Renal and cardiovascular morbidity after partial or radical nephrectomy. Cancer (Phila) 112:511-520
8. Stewart JH, Buccianti G, Agodoa L et al (2003) Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New Zealand. J Am Soc Nephrol 14:197-207
9. Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alpha in metastatic renal-cell carcinoma. N Engl J Med 356:115-124
10. Rini BI, Escudier B, Tomczak P et al (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378:1931-1939
11. Lunardi G, Armirotti A, Nicodemo M et al (2009) Comparison of temsirolimus pharmacokinetics in patients with renal cell carcinoma not receiving dialysis and those receiving hemodialysis: a case series. Clin Ther 31:1812-1819
12. Motzer RJ, Bacik J, Murphy BA et al (2002) Interferon-alpha as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20:289-296
13. Fukuhara S, Bito S, Green J (1998) Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan. J Clin Epidemiol 51:1037-1044
14. Fukuhara S, Ware JE Jr, Kosinski M (1998) Psychometric and clinical tests of validity of the Japanese SF-36 Health Survey. J Clin Epidemiol 51:1045-1053
15. Josephs D, Hutson TE, Cowey CL et al (2011) Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis. BJU Int 108:1279-1283
16. Masini C, Sabbatini R, Porta C et al (2012) Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey. BJU Int (Epub ahead of print)
17. Kennoki T, Kondo T, Kimata N et al (2011) Clinical results and pharmacokinetics of sorafenib in chronic hemodialysis patients with metastatic renal cell carcinoma in a single center. Jpn J Clin Oncol 41:647-655
18. Lamm W, Vogl UM, Bojic M et al (2012) Safety and efficacy of temsirolimus in heavily pretreated patients with metastatic renal cell carcinoma. Acta Oncol 51:101-106
19. Kuru TH, Huber J, Hatiboglu G et al (2011) Initial experience with temsirolimus in 2nd-, 3rd- and 4th-line therapy for metastatic renal cell cancer: good clinical response. Urol Int 86:256-260
20. Awdishu L, Bouchard J (2011) How to optimize drug delivery in renal replacement therapy. Semin Dial 24:176-182
21. Hiraike M, Hiraki Y, Misumi N et al (2012) Pharmacokinetics of carboplatin in a hemodialysis patient with small-cell lung cancer. Cancer Chemother Pharmacol 69:845-848
22. Cella D, Li JZ, Cappelleri JC et al (2008) Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon α: results from a phase III randomized trial. J Clin Oncol 26:3763-3769
23. Miyake H, Kurahashi T, Yamanaka K et al (2010) Impact of sorafenib on health-related quality of life in Japanese patients with metastatic renal cell carcinoma: a prospective evaluation. BJU Int 106:1643-1647
24. Miyake H, Harada KI, Kusuda Y et al (2011) Health-related quality of life in Japanese patients with metastatic renal cell carcinoma treated with sunitinib. Int J Clin Oncol (Epub ahead of print)
25. Fujisawa M, Ichikawa Y, Yoshida K et al (2000) Assessment of health-related quality of life in renal transplant and hemodialysis patients using the SF-36 health survey. Urology 56:201-206